Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
06/2003
06/11/2003EP0848755B1 Vegf-related protein
06/11/2003EP0638119B1 Chimeric receptor genes and cells transformed therewith
06/11/2003CN1423700A Multifunctional polypeptides comprising a binding site to and epitope of the NKG2D receptor complex
06/11/2003CN1423695A Antisense oligonucleotides
06/11/2003CN1423693A Method for the production of vitamin A
06/11/2003CN1423660A Antibodies
06/11/2003CN1423659A Recombinant gelatins
06/11/2003CN1423658A Modulation of human sodium channels in dorsal root ganglia
06/11/2003CN1423657A Inter feron-alpha induced gene
06/11/2003CN1423563A Pancreatic stem cells and their use in transplantation
06/11/2003CN1423523A Human ex vivo immune system
06/11/2003CN1422950A Recombinant gland-related virus expressing human blood angiotonin II receptor I antisense gene and preparation method thereof
06/10/2003US6576759 Antiproliferative agents; anticancer agents; rheumatic disorders; administering nucleotide
06/10/2003US6576758 Nucleic acid constructs containing hybrid promoters
06/10/2003US6576751 FADD-like anti-apoptotic molecules, methods of using the same, and compositions for and methods of making the same
06/10/2003US6576750 Isolated cDNA or RNA molecule that encodes a protein of given amino acid sequence; cDNA or RNA comprising a nucleotide sequence; can use for vaccines and chemotherapeutic drugs
06/10/2003US6576669 Use of an LTB4 antagonist for the treatment or prevention of diseases caused by increased expression of mucin genes
06/10/2003US6576618 Cholesterol containing cationic liposome having gene encoding insulin like growth factor I
06/10/2003US6576609 Methods and compositions for generating angiostatin
06/10/2003US6576608 Stimulating tyrosine phosphorylation of Flt4 tyrosine kinase receptor in Flt4-expressing cell
06/10/2003US6576607 Methods using CNS neurite outgrowth modulators
06/10/2003US6576463 Nucleic acid molecule comprising adenoviral region with inverted terminal repeats; retroviral region comprising promoter and long terminal repeats; provides efficient transduction of cells and stable integration
06/10/2003US6576456 Chimeric adenovirus fiber protein
06/10/2003US6576443 Adjustment of gene expression
06/10/2003US6576439 Contacting protein of given sequence with a test compound and detecting modulating activity; drug screening; can use for treatment of inflammatory conditions
06/10/2003US6576437 Stimulus-inducible protein kinase complex and methods of use therefor
06/10/2003US6576243 Polynucleotide vaccine formula against porcine reproductive and respiratory pathologies
06/10/2003US6576218 Transplacental delivery of oligonucleotides
06/10/2003CA2191795C Antisense oligonucleotide modulation of raf gene expression
06/07/2003CA2376719A1 A method to improve the safety of gene therapy
06/05/2003WO2003046581A2 Methods for diagnosis and treatment of epithelial-derived cancers,such as colorectal cancers and kidney cancers
06/05/2003WO2003046506A2 Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies
06/05/2003WO2003046190A1 Optimized production of viral vectors derived from paroviruses in packaging and production cells by hsv infection or treatment with dna methylation inhibitors
06/05/2003WO2003046189A1 Flavivirus vaccine delivery system
06/05/2003WO2003046185A1 Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
06/05/2003WO2003046181A1 Non-human transgenic mammals used as models for human pathologies originating from stem cells
06/05/2003WO2003046180A2 Human cdnas and proteins and uses thereof
06/05/2003WO2003046179A2 G-protein coupled receptor lustr2 and uses thereof
06/05/2003WO2003046171A1 A method for combined sequential agent delivery and electroporation for cell structures and use thereof
06/05/2003WO2003046170A1 A method for combined parallel agent delivery and electroporation for cell structures and use thereof
06/05/2003WO2003046168A1 Regulation of human cation transporting atpase
06/05/2003WO2003046166A1 Suicide gene systems
06/05/2003WO2003046138A2 Genetically stable expression vector
06/05/2003WO2003046135A2 Osteopontin-related compositions and methods
06/05/2003WO2003046134A2 Expression of polypeptides in rod outer segment membranes
06/05/2003WO2003046127A2 Tumor endothelial marker 5 molecules and uses thereof
06/05/2003WO2003046124A2 Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
06/05/2003WO2003046047A1 Medical polymers and use thereof
06/05/2003WO2003046006A1 Polynucleotides encoding nexin-related serine protease inhibitor
06/05/2003WO2003045999A2 Human vanilloid receptor protein and polynucleotide sequence encoding same
06/05/2003WO2003045973A2 Peptides with growth inhibitory action
06/05/2003WO2003045965A2 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
06/05/2003WO2003045439A1 Genetic remedies for neurodegenerative diseases
06/05/2003WO2003045425A1 Muscle transcription factors
06/05/2003WO2003045420A2 Use of t-cell immune response cdna 7 (tirc7) for modulation of angiogenesis and/or neovascularization
06/05/2003WO2003045415A2 Self-assembling p53 peptides as gene delivery vehicles
06/05/2003WO2003045335A2 Stem cell screening and transplantation therapy for hiv infection
06/05/2003WO2003045325A2 Dopaminergic stimulatory factor
06/05/2003WO2003045318A2 Manipulation of cytokine levels using cd83 gene products
06/05/2003WO2003045317A2 Therapeutic protein and treatments
06/05/2003WO2003045316A2 Polynucleotide therapy
06/05/2003WO2003024478A9 Treatment of central nervous system disorders by use of pdgf or vegf
06/05/2003WO2003010201A9 Blood group antigen fusion polypeptides and methods of use thereof
06/05/2003WO2003004526A3 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines
06/05/2003WO2003000296A3 Treatment and diagnostic of b cell chronic lymphocytic leukaemia
06/05/2003WO2002102306A3 Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
06/05/2003WO2002081665A3 Implantation serine proteinases
06/05/2003WO2002081007A3 Methods of isolating blood components using a centrifuge and uses thereof
06/05/2003WO2002064157A9 Localized myocardial injection method for treating ischemic myocardium
06/05/2003WO2002059350A3 Use of sialyltransferases for diagnosing and treating tumorous diseases
06/05/2003WO2002048351A3 A method for in vitro molecular evolution of protein function
06/05/2003WO2002040673A3 Compositions and methods relating to lung specific genes and proteins
06/05/2003WO2002007754A3 New use
06/05/2003US20030106082 Transgenic stem cells, formed by dissociating blastomeres, are cultured, impregnated within surrogate; animals models; gene therapy
06/05/2003US20030106077 Transfection of noncircular vector into stem cell genome by way of homologous recombination; gene therapy
06/05/2003US20030105318 G-protein transmembrane domain; protein synthesis inhibitor; neurotransmitter
06/05/2003US20030105311 Oligonucleotides having A-DNA form and B-DNA form conformational geometry
06/05/2003US20030105302 Fibroblast cell growth factor; for diagnosis, detection and prevention of skin, cancer, brain, glandular, cell differentiation/ proliferative and placental disorders; antiproliferative agents, antitumor agents
06/05/2003US20030105277 Tat transport proteins; antiproliferative agents; antitumor agents
06/05/2003US20030105057 Modulating the rate and/or amount of a cellular process selected from the group consisting of cell growth, cell detachment and cell migration, and cellular apoptosis by altering the RECEPTOR/PTK-STAT pathway of cell
06/05/2003US20030105055 Methods and compositions for the treatment of ocular diseases
06/05/2003US20030105054 For eliciting an immune response and enhancing current therapeutic modalities for the treatment of cancer; stimulates T cell proliferation
06/05/2003US20030105052 Oligoribonucleotide derivatives for specific inhibition of gene expression
06/05/2003US20030105050 Disorders caused by overproduction of collagen fibres, for example, liver cirrhosis, kidney, liver and heart fibrosis, scleroderma, hypertrophic scars and keloids
06/05/2003US20030105048 For in vitro, in vivo or ex vivo transfer of nucleic acids into cells or for the visualization of the nucleic acids administered, by fluorescence
06/05/2003US20030105047 Surgically implanting an intraparenchymal catheter having a port; discharging predetermined dosage of capable of altering a nucleotide in a DNA sequence of a gene to convert a codon in a protein-coding region of the gene into a stop codon in brain
06/05/2003US20030105046 Therapy of amyotrophic lateral sclerosis and head trauma injury by inhibiting interleukin converting enzyme (ICE) by gene therapy
06/05/2003US20030105039 Introducing into eukaryotic cell recombinase and single-stranded targeting polynucleotides which are complementary and each having a homology clamp that corresponds to or is complementary to preselected target DNA
06/05/2003US20030105008 Geminin and Orc3N inhibit replication of herpesviruses, papillomaviruses, and polyomaviruses
06/05/2003US20030105004 Novel morphogenic protein compositions of matter
06/05/2003US20030104998 Secreted and transmembrane polypeptides and nucleic acids encoding the same
06/05/2003US20030104987 Methods of using the hyaluronan receptor for endocytosis
06/05/2003US20030104985 Anticarcinogenic agent is conjugated with a nucleic acids, for cancer treatment; a kit for detection; chemical intermediates
06/05/2003US20030104977 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
06/05/2003US20030104973 Purified, isolated and cloned nucleic acid polynucleotide encoding hypoxia-regulating genes and the proteins and antibodies specifically bind these proteins; genetic engineering
06/05/2003US20030104970 Modulating the growth state of an epithelial cell by ectopically contacting the epithelial cell, in vitro or in vivo, with hedgehog polypeptide or patched therapeutic to promote or inhibit of proliferation of epithelial cell
06/05/2003US20030104627 Method and an apparatus for generating shockwave, a method and an apparatus for accelerating particles, an apparatus for delivering drugs, and a method and an apparatus for delivering DNA
06/05/2003US20030104626 Packaging systems for human recombinant adenovirus to be used in gene therapy
06/05/2003US20030104625 Novel oncolytic adenoviral vectors
06/05/2003US20030104624 Novel vector constructs
1 ... 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 ... 870